SAB Biotherapeutics (SABS) Profit After Tax (2020 - 2026)
SAB Biotherapeutics (SABS) reported Profit After Tax of -$18.9 million for Q1 2026, down 263.09% on a YoY basis from $11.6 million in Q1 2025, and down 11.91% quarter-over-quarter from -$16.9 million in Q4 2025.
SAB Biotherapeutics (SABS) Profit After Tax (2020 - 2026) Analysis & Trends
SAB Biotherapeutics has reported Profit After Tax for 7 years, with the latest figure at -$18.9 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax fell 263.09% year-over-year to -$18.9 million; the trailing twelve-month figure through Mar 2026 stood at -$398429.0 (up 98.84% YoY), and the FY2025 full-year result was $13.3 million, up 138.92% from the prior year.
- Profit After Tax for Q1 2026 stood at -$18.9 million, down from -$16.9 million in the prior quarter.
- The five-year high for Profit After Tax was $45.4 million in Q3 2025, with the low at -$22.9 million in Q4 2023.
- Historically, Profit After Tax has averaged -$5.9 million across 5 years, with a median of -$7.3 million in 2024.
- Annual changes were most pronounced in 2023 — Profit After Tax sank 845.93% — and 2025, when it surged 539.11%.
- SAB Biotherapeutics' Profit After Tax stood at -$7.9 million in 2022, then plunged by 190.26% to -$22.9 million in 2023, then soared by 50.15% to -$11.4 million in 2024, then plunged by 47.97% to -$16.9 million in 2025, then fell by 11.91% to -$18.9 million in 2026.
- The last three Profit After Tax figures came in at -$18.9 million (Q1 2026), -$16.9 million (Q4 2025), and $45.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | -18.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.87 Mn |
| Dec 31, 2025 | -16.86 Mn |
| Sep 30, 2025 | 45.45 Mn |
| Jun 30, 2025 | -10.11 Mn |
| Mar 31, 2025 | -5.20 Mn |
| Dec 31, 2024 | -11.39 Mn |
| Sep 30, 2024 | -10.35 Mn |
| Jun 30, 2024 | -7.34 Mn |
| Mar 31, 2024 | -5.03 Mn |
| Dec 31, 2023 | -22.86 Mn |
| Sep 30, 2023 | -5.10 Mn |
| Jun 30, 2023 | -6.88 Mn |
| Mar 31, 2023 | -7.35 Mn |
| Dec 31, 2022 | -7.87 Mn |
| Sep 30, 2022 | -7.08 Mn |
| Jun 30, 2022 | -4.78 Mn |
| Mar 31, 2022 | 985,863.00 |
| Dec 31, 2021 | -11.55 Mn |
| Sep 30, 2021 | -4.06 Mn |
| Jun 30, 2021 | -2.94 Mn |